Skip to main content

Profile: Richard Bond

Richard Bond
Richard A. Bond, Ph.D., FBPhS
Professor of Pharmacology

Health 2
University of Houston College of Pharmacy
4849 Calhoun Road, Room 5015
Houston, TX 77204-5037
Office: 713-743-1210
Fax: 713-743-1884


B.A. Science, St. Thomas of Villanova, Miami, Fla.
B.S. Pharmacy, University of Houston College of Pharmacy, Houston, Texas
Ph.D. Pharmacology, University of Houston College of Pharmacy, Houston, Texas

Research Interests

  • Pharmacology of receptor theory
  • Characterization and classification of G protein-coupled receptors


U.S. Patent No. 7,528,175: Method of treating airway diseases with beta-adrenergic inverse agonists. Awarded May 5, 2009.

Awards & Honors

  • Honorary Fellow, British Pharmacological Society, 2017
  • Fellow, British Pharmacological Society, 2016
  • University of Houston Provost’s 'Certificate of Excellence' awarded for 'Extraordinary Achievements' by the UH Provost, 2015
  • R.A. Bond was identified as one of 42 ‘Major figures’ in pharmacological research in a special commissioned review about the history of pharmacology: Winquist, R.J., Mullane, K. and Williams, M.: The Rise and Fall of Pharmacology – (Re-) defining the Discipline? Biochem Pharmacol. 87: 4 – 24, 2014
  • Commendation, Medical Futures Innovation Awards, 2011
  • Faculty Excellence Award, University of Houston College of Pharmacy, 2000 and 1995
  • Established Investigator’s Award, American Heart Association, 1999
  • Named one of the 100 Most Influential Hispanics by Hispanic Business magazine, 1997
  • One of University of Houston College of Pharmacy’s 50 Outstanding Alumni celebrating the College's 50th Anniversary, 1997
  • Teaching Award from Council of Campus Leaders, University of Houston, 1995


  • Cardiovascular Pharmacology
  • Neuropharmacology
  • PCOL 6370 Advanced Pharmacology
  • PCOL 7350 Cellular Pharmacology
  • Pharmacology I
  • Skills Laboratory

Peer-reviewed Publications

Baker FL, Bigley AB, Agha NH, Pedlar CR, O'Connor DP, Bond RA, Bollard CM, Katsanis E, Simpson RJ. Systemic β-Adrenergic Receptor Activation Augments the ex vivo Expansion and Anti-Tumor Activity of Vγ9Vδ2 T-Cells. Front Immunol. 2020 Jan 24;10:3082. doi: 10.3389/fimmu.2019.03082. eCollection 2019.

Islas JF, Abbasgholizadeh R, Dacso C, Potaman VN, Navran S, Bond RA, Iyer D, Birla R, Schwartz RJ. β-Adrenergic stimuli and rotating suspension culture enhance conversion of human adipogenic mesenchymal stem cells into highly conductive cardiac progenitors. J Tissue Eng Regen Med. 2020 Feb;14(2):306-318. doi: 10.1002/term.2994. Epub 2020 Jan 10.

Michel MC, Bond RA, Summers RJ. Adrenoceptors-New roles for old players. Br J Pharmacol. 2019 Jul;176(14):2339-2342. doi: 10.1111/bph.14701.

Bond RA, Lucero Garcia-Rojas EY, Hegde A, Walker JKL. Therapeutic Potential of Targeting ß-Arrestin. Front Pharmacol. 2019 Mar 6;10:124. doi: 10.3389/fphar.2019.00124. eCollection 2019. Review.

Graff RM, Kunz HE, Agha NH, Baker FL, Laughlin M, Bigley AB, Markofski MM, LaVoy EC, Katsanis E, Bond RA, Bollard CM, Simpson RJ. β2-Adrenergic receptor signaling mediates the preferential mobilization of differentiated subsets of CD8+ T-cells, NK-cells and non-classical monocytes in response to acute exercise in humans. Brain Behav Immun. 2018 Nov;74:143-153. doi: 10.1016/j.bbi.2018.08.017. Epub 2018 Aug 30.

Agha NH, Baker FL, Kunz HE, Graff R, Azadan R, Dolan C, Laughlin MS, Hosing C, Markofski MM, Bond RA, Bollard CM, Simpson RJ. Vigorous exercise mobilizes CD34+ hematopoietic stem cells to peripheral blood via the β2-adrenergic receptor. Brain Behav Immun. 2018 Feb;68:66-75. doi: 10.1016/j.bbi.2017.10.001. Epub 2017 Oct 7.

Nguyen LP, Al-Sawalha NA, Parra S, Pokkunuri I, Omoluabi O, Okulate AA, Windham Li E, Hazen M, Gonzalez-Granado JM, Daly CJ, McGrath JC, Tuvim MJ, Knoll BJ, Dickey BF, Bond RA. β2-Adrenoceptor signaling in airway epithelial cells promotes eosinophilic inflammation, mucous metaplasia, and airway contractility. Proc Natl Acad Sci U S A. 2017 Oct 24;114(43):E9163-E9171. doi: 10.1073/pnas.1710196114. Epub 2017 Oct 9. PMID:29073113

Joshi R, Valdez D, Kim H, Eikenburg DC, Knoll BJ, Bond RA. Effects of β-blockers on house dust mite-driven murine models pre- and post-development of an asthma phenotype. Pulm Pharmacol Ther. 2017 Oct;46:30-40. doi: 10.1016/j.pupt.2017.07.004. Epub 2017 Jul 17. PMID: 28729042

Graff RM, Kunz H, Agha NH, Baker FL, Azadan R, Rooney BV, M PL, Bond RA, Bollard CM, LaVoy EC, Simpson RJ. Antigen-specific CD8+ T-cells are mobilized via ß2-adrenergic receptor signaling. Med Sci Sports Exerc. 48(5 Suppl):744, 2016. PMID:27361300

Forkuo GS, Kim H, Thanawala VJ, Al-Sawalha N, Valdez D, Joshi R, Parra S, Pera T, Gonnella PA, Knoll BJ, Walker JK, Penn RB, Bond RA. Phosphodiesterase 4 Inhibitors Attenuate the Asthma Phenotype Produced by β2-Adrenoceptor Agonists in Phenylethanolamine N-Methyltransferase-Knockout Mice. Am J Respir Cell Mol Biol. 2016 Aug;55(2):234-42. doi: 10.1165/rcmb.2015-0373OC. PMID: 26909542

Bond RA, Thanawala VJ, Parra S, Leff P. Differences in asthma study models and the effectiveness of β2 -adrenoceptor ligands: response to Lipworth et al. Br J Pharmacol. 2016 Jan;173(1):250-1. doi: 10.1111/bph.13334. PMID: 26687674

J. Morgan Knight, Garbo Mak, Joanne Shaw, Catherine McDermott, Luz Roberts, Ran You, Xiaoyi Yuan, Alexander B. Seryshev, Valentine O. Millien, Yuping Qian, Li-Zhen Song, Vincent Frazier, Julia K. Walker, Richard A. Bond, Pijus K. Mandal, Pietro Morlacchi, Amber Luong, Farrah Kheradmand, John S. McMurray, and David B. Corry: Long-Acting ß-Agonists Enhance Allergic Lung Disease. PLoS One. 25:10 (11), 2015.

Thanawala, V.J., Valdez, D., Radhika, J., Forkuo, G.S., Parra, S., Knoll, B.J., Bouvier, M., Leff. P., and Bond, R.A.: Beta-blockers have differential effects on the murine asthma phenotype. Br J Pharmacol. 172:4833-46. 2015. PMID:26211486

Al-Sawalha, N., Pokkunuri, I., Omoluabi, O., Kim, H., Thanawala, V.J., Hernandez, A., Bond, R.A., and Knoll, B.J.: Epinephrine activation of the ß2-adrenoceptor is required for IL-13-induced mucin production in human bronchial epithelial cells. PLoS One. 2015 Jul 10:10,2015. PMID:26161982

Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA, Gilchrist A, Hoyer D, Insel PA, Izzo AA, Lawrence AJ, MacEwan DJ, Moon LD, Wonnacott S, Weston AH, McGrath JC. Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol. 2015 Jul;172(14):3461-71. doi: 10.1111/bph.12856. PMID: 26114403

Michel MC, Seifert R, Bond RA. Dynamic bias and its implications for GPCR drug discovery. Nat Rev Drug Discov. 2014 Nov;13(11):869. doi: 10.1038/nrd3954-c3. Epub 2014 Oct 17. PMID: 25323926

Bond RA. The intrinsic bias of generalizations. Am J Respir Crit Care Med. 2014 Feb 1;189(3):359. doi: 10.1164/rccm.201306-1109LE. PMID: 24484333

Penn RB, Bond RA, Walker JK. GPCRs and arrestins in airways: implications for asthma. Handb Exp Pharmacol. 2014;219:387-403. doi: 10.1007/978-3-642-41199-1_20. PMID: 24292841

Forkuo GS, Thanawala VJ, Al-Sawalha N, Bond RA, Walker JK. Reply: Adverse effects of long-acting beta-agonists on airway hyperresponsiveness. Am J Respir Cell Mol Biol. 2013 Sep;49(3):502. doi: 10.1165/rcmb.2013-0161LE. PMID: 23991664

Vollert C, Forkuo GS, Bond RA, Eriksen JL. Chronic treatment with DCPCX, an adenosine A(1) antagonist, worsens long-term memory. Neurosci Lett. 2013 Aug 26;548:296-300. doi: 10.1016/j.neulet.2013.05.052. Epub 2013 Jun 6. PMID: 23748072

Thanawala VJ, Forkuo GS, Al-Sawalha N, Azzegagh Z, Nguyen LP, Eriksen JL, Tuvim MJ, Lowder TW, Dickey BF, Knoll BJ, Walker JK, Bond RA. β2-Adrenoceptor agonists are required for development of the asthma phenotype in a murine model. Am J Respir Cell Mol Biol. 2013 Feb;48(2):220-9. doi: 10.1165/rcmb.2012-0364OC. Epub 2012 Nov 29. PMID: 23204390

Nguyen LP, Singh B, Okulate AA, Alfaro VY, Tuvim MJ, Dickey BF, Bond RA. Complementary anti-inflammatory effects of a β-blocker and a corticosteroid in an asthma model. Naunyn Schmiedebergs Arch Pharmacol. 2012 Feb;385(2):203-10. doi: 10.1007/s00210-011-0692-0. Epub 2011 Oct 2. PMID: 21964666

Peng H, Bond RA, Knoll BJ. The effects of acute and chronic nadolol treatment on β2AR signaling in HEK293 cells. Naunyn Schmiedebergs Arch Pharmacol. 2011 Feb;383(2):209-16. Epub 2011 Jan 12.

Walker JK, Penn RB, Hanania NA, Dickey BF, Bond RA. New perspectives regarding β(2)-adrenoceptor ligands in the treatment of asthma. Br J Pharmacol. 2011 May;163(1):18-28. doi: 10.1111/j.1476-5381.2010.01178.x. Review.

Hanania NA, Mannava B, Franklin AE, Lipworth BJ, Williamson PA, Garner WJ, Dickey BF, Bond RA. Response to salbutamol in patients with mild asthma treated with nadolol. Eur Respir J. 2010 Oct;36(4):963-5.

Dickey BF, Walker JK, Hanania NA, Bond RA. beta-Adrenoceptor inverse agonists in asthma. Curr Opin Pharmacol. 2010 Jun;10(3):254-9. Review.

Hanania, N.A., Dickey, B.F. and Bond, R.A.: Clinical Implications of the Intrinsic Efficacy of Beta-Adrenoceptor Drugs in Asthma: Full, Partial and Inverse Agonism. Current Opinion in Pulm Med, 16: 1-5, 2010.

Nguyen, L., Lin, R., Omoluabi, O., Hanania, N., Tuvim, M., Knoll, B., Dickey, B.F., Bond, R.A.: βß2-adrenoceptor signaling is required for the development of the asthma phenotype in a murine model. Proc. Nat. Acad. Sci. 101: 4948 – 4953, 2009.

Nguyen, L., Omoluabi, Parra, S., Frieska, J.M, Clement, C., Ammar-Aouchiche, Z., Ho, S.B., Ehre, C., Kessimer, M., Knoll, K.J., Tuvin, M., Dickey, B.F. and Bond, R.A.: Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol. 38: 256-262, 2008.

Hanania, N.A, Singh, S., Eli-Wali, R., Flasner, M., Franklin, A.E., Garner, W.J., Parra, S., Ruoss, S.J., Shardonofsky, F., O’Connor, B.J., Page, C. and Bond, R.A.: The safety and effects of the beta-blocker, nadolol, for the chronic treatment of asthma; an open-label pilot study. Pulmonary Pharmacol. & Ther. 21: 134–141, 2008.

Lin, R., Peng, H., Nguyen, L., Dudekula, N.B., Shardonofsky, F., Knoll, B., Parra, S. and Bond, R.A.: Changes in ß2-adrenoceptors and other signaling proteins produced by chronic administration of ‘ß-blockers’ in a murine asthma model. Pulmonary Pharmacol. & Ther. 21: 115–124, 2008.

Bond, R.A., Spina, D., Parra, S. and Clive, C.P. (2007). Getting to the heart of asthma; can ‘beta-blockers’ be used to treat asthma? Pharmacol & Ther.. 115: 360-374, 2007.

Parra, S. and Bond, R.A.: Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant? Current Opinions Pharmacol., 7: 146-150, 2007.

Bond, R.A.: A proposal for a national program reporting beneficial drug responses, analogous to the existing program to detect adverse drug responses. Med. Hypoth. 66: 10-13, 2006.

Bond, R.A. and IJzjerman, A.P.: Recent developments in constitutive receptor activity and inverse agonism and their potential for drug discovery. Trends Pharmacol. Sci., 2: 92 – 96, 2006.

Dudekula, N., Arora, V., Callaerts-Vegh, Zs. and Bond, R.A.: The temporal hormesis of drug therapies. Dose-Response 3: 414-424, 2005.

Invited Publications

Boulanger CM, Baretella O, Blaise G, Bond RA, Cai Y, Chan CKY, Chataigneau T, Chen MJ, Chen H, Cheng Y, Clement DL, Cohen RA, Collis M, Danser AHJ, de Mey J, Detremmerie CMS, Duprez D, Feletou M, Flavahan N, Gao Y, Guo Y, Hoeffner U, Houston DS, Huang IB, Huang Y, Iliano S, Junquero D, Katusic ZS, Komori K, Lee MYK, Leung SWS, Li Z, Liang SC, Liu JTC, Luscher TF, Michel F, Miller VM, Mombouli JV, Morrison K, Muldoon SM, O'Rourke S, Perrault L, Quignard JF, Rusch NJ, Sanchez-Ferrer CF, Schini-Kerth V, Shen K, Shi Y, Song E, Sun KWY, Taddei S, Tang EHC, Tuncer M, van den Ende R, Vedernikov Y, Verbeuren TJ, Webb C, Weigert A, Wong KHK, Xu C, Yang K, Ying F, Zellers T, Zhao Y, Zou Q, Shimokawa H; Professor Paul M. Vanhoutte’s former fellows. Tribute to Paul M. Vanhoutte, MD, PhD (1940-2019). Arterioscler Thromb Vasc Biol. 2019 Dec;39(12):2445-2447. doi: 10.1161/ATVBAHA.119.313461. Epub 2019 Nov 26.

Bond, R.A., Thanawala, V.J., Parra, S. and Leff, P.: Differences in asthma study models and the effectiveness of ß2-adrenoceptor ligands; response to Lipworth et. al. Br J Pharmacol.173: 250, 2016.

Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA, Gilchrist A, Hoyer D,Insel P, Izzo AA, Lawarence AJ, MacEwan DJ, Moon LD, Wonnacott S, Weston AH, McGrath JC:Experimental design and analysis and their reporting: new guidance for publication in BJP.Br J Pharmacol. 172: 3461 – 3471, 2015.

Bond R.A., Bylund DB, Eikenburg DC, Hieble JP, Hills R, Minneman KP, et al. (2014). Adrenoceptors: ß2-adrenoceptor Last modified on 17/09/2014. Accessed on 22/02/2015. IUPHAR/BPS Guide to PHARMACOLOGY,

Forkuo, G.S., Thanawala, V.J., Al-Sawalha, N., Walker, J.K., and Bond, R.A.: Response to Lipworth Commentary, Am J Respir Cell Mol Biol., 49: 502, 2013.

Bond RA, Giles H. For the love of paradox: from neurobiology to pharmacology. Behav Pharmacol. 2011 Sep;22(5-6):385-9.

Bond RA, Spina D. Special issue of BJP on respiratory pharmacology. Br J Pharmacol. 2011 May;163(1):1-3. doi: 10.1111/j.1476-5381.2011.01239.x.

Michel MC, Harding SE, Bond RA. Are there functional β₃-adrenoceptors in the human heart? Br J Pharmacol. 2011 Feb;162(4):817-22. doi: 10.1111/j.1476-5381.2010.01005.x. Review.

Charlton SJ, Bond RA. BJP issue on drug discovery. Br J Pharmacol. 2010 Nov;161(6):1201-2. doi: 10.1111/j.1476-5381.2010.01028.x.

McGrath JC, Bond RA. Sir James Black (1924-2010). Br J Pharmacol. 2010 Jul;160 Suppl 1:S2.

Bond, R.A., Omoluabi, O. And Nugyen, L.: Beta-blockers and beta-agonists in asthma – unraveling a paradox. Resp. Drug Delivery 1: 15 – 24, 2009.

Bond, R. A., Parra, S., Hills, R. A., Bylund, D. B., Bouvier, M., Clarke, D. E., Eikenberg, D. C., Hieble, J. P., Koblika, B. K., Langer, S. Z., Lefkowitz, R. J., Minneman, K. P., Ruffolo, R. R. and Strosberg, A. D.: Adrenoceptors - beta(3), IUPHAR Receptor database. (doi: 10.1786/304416402524). Also, middle author on remaining 8 adrenoceptor classifications. 2005.

Book Chapters

Penn, R.B., Bond, R.A. and Walker, J.K.L.: For Handbook of Experimental Pharmacology: “GPCRs and Arrestins in Airways: Implications for Asthma”, Ed. Y. Gurevich. Springer-Verlag Berlin Heidelberg, 219: 387-403, 2014.

Bond, R.A. and Lefkowitz, R.J.: Historical background and introduction. G protein-coupled receptors as drug targets: Analysis of activation and constitutive activity. Ed. T. Weiland and R. Seifert. Wiley-VCH. 2006.

Bond, R.A., Evans, K.J. and Callaerts-Vegh, Zs.: From inverse agonism to paradoxical pharmacology. Ed. A.P. Ijzerman. Inverse Agonism.  Elsevier Science. 10: 27-37, 2003

Bond, R.A., Milligan, G. and Bouvier, M.:  Inverse Agonism. For Handbook of Experimental Pharmacology, Volume:  "The Pharmacology of Functional, Biochemical, and Recombinant Receptor Systems", Ed. T. Kenakin and J. Angus, 2001.

Bond, R.A. and Bouvier, M.: Inverse agonists and rationale drug design. In: Receptor-Based Drug Design, p. 363-377, Ed. P. Leff, Marcel Dekker Inc., N.Y., N.Y. 1998.

Kenakin, T.P. and Bond, R.A.: Theoretical and practical advantages and limitations of techniques used in functional pharmacological classification of receptors. In: Trends in Receptor Research. Eds., Angeli, P., Gulini, U., and Quaglia, W., Elseviers Science Publishers B.V., England, 1992.

Bond, R.A., Charlton, K.G., Blue, D.R., and Clarke, D.E.: Prejunctional 5-HT receptors mediating inhibition of transmitter release from peripheral cholinergic and noradrenergic nerve terminals. In: Serotonin (Proceedings of the Heron Island Meeting, September, 1987). Eds., Mylecharane, E. J., Angus, J.A., de la Lande, I.S., and Humphrey, P.P.A., MacMillian Press Limited, England, 1989.


Hui Peng, Brian Knoll, Richard A. Bond. Novel effects of nadolol on desensitization and heterologous sensitization systems. IUPHAR (2006), Beijing, China.

Rui Lin, Sergio Parra, Vikas Arora, Becky Chan, Joanna Frieske, Brian Knoll, Richard A. Bond. Potential mechanisms of the beneficial effect of chronic nadolol treatment in a murine model of asthma. IUPHAR (2006), Beijing, China.

Sergio Parra, Carlos Rodriguez, Rui Lin, Zoma Omoluabi, Joanna Frieske, Felix Shardonofsky, Brian Knoll, Richard A. Bond. Muscarinic M2 receptors modulate airway responses to methacholine in a murine model of asthma. IUPHAR (2006), Beijing, China.

Invited Lectures

Biased signaling by beta-blockers; the good, the bad, and the neutral. Keynote speaker, Young Investigators’ Meeting on Airway Smooth Muscle Physiology, King’s College London, London, UK, 2015.

Biased signaling by beta-blockers; the good, the bad, and the neutral. Respiratory Department Seminar Series, Cleveland Clinic, Cleveland, OH, USA, 2015.

ß2-adrenoceptor signaling in asthma; which way is up? Center for Translational Medicine and Department of Pharmacology Seminar Series, Temple University, Philadelphia, PA, USA, 2015.

ß2-adrenoceptor signaling in asthma; which way is up? GPCR satellite symposium, Kruger National Park, South Africa, 2014.

Biased signaling by beta-blockers; the good, the bad, and the neutral. The Prince Charles Hospital, Thoracic Grand Rounds, Brisbane, Australia, 2014.

Biased signaling by beta-blockers; the good, the bad, and the neutral. University of Melbourne, Dept. of Pharmacology, Melbourne, Australia, 2014.

Time, the forgotten variable in drug response; Lessons from heart failure and asthma. Texas Heart Institute, Houston, TX, USA, 2012.

Time, the forgotten variable in drug response. Pasteur Institute, Paris, France, 2012.

ß2-adrenoceptor agonists are required for development of the asthma phenotype. Lung Research Day, Houston, TX, USA, 2012.

Short presentation and panelist invitee for ‘Evolutionary Medicine Conference’ Stanford Medical School, Palo Alto, CA, USA, 2012.

New GPCR and cAMP (or are they cAMP?) paradigms: pathophysiological and therapeutic relevance. BPS focused symposium “Novel cAMP signaling paradigms: New insights into the development and progression of chronic inflammatory disease. London, UK, 2011.

Think the impossible: beta-blockers for treating asthma. Pro and Con debate at EAACI, Istanbul, Turkey, 2011

Taking a lesson from heart failure.  Can 'ß-blockers be used in the treatment of asthma?' University of Texas Medical School – Houston. Biochemistry and Molecular Biology Seminar Series, 2011.

Beta-blockers and beta-agonists in asthma: unraveling a paradox. McMaster University Honours Biology & Pharmacology Program "3rd Annual Biology & Pharmacology Lectureship," 2010.

Getting to the heart of asthma – can beta-blockers be used as chronic asthma therapy? Systems Biology of Human Disease Conference, Boston, MA, USA, 2009.

Beta-blockers and beta-agonists in asthma: unraveling a paradox. Respiratory Drug Delivery (RDD), Lisbon, Portugal, 2009.

Paradoxical pharmacology; Can beta-blockers be used to treat asthma? William Harvey Research Institute Seminar Series, London, UK, 2008.

Debate: Beta-2 adrenoceptor agonists and corticosteroids are all we need for asthma. Presenting the ‘Against’ position. 5th James Black Conference – Cutting EdgeConcepts in Lung Pharmacology, Crieff Hydro, Perthshire, Scotland, 2007.

Special ‘Hot Topic’ Session: Further explanation of the worldwide increase in morbidity and mortality from asthma. European Respiratory Society Conference, Stockholm, Sweden, 2007.

Use of beta-blockers in chronic heart failure and asthma bronchiale. German Congress of Anaethesiology, Hamburg, Germany, 2007.

'Paradoxical Pharmacology'; A way forward in asthma therapy? University of Amsterdam (AMC) Department of Experimental & Clinical Experimental Anesthesiology. Amsterdam, The Netherlands, 2007.

Getting to the heart of asthma; can beta-blockers be used to treat asthma? Special Symposium of the British Pharmacological Society’s 75th Anniversary Celebration, Oxford, UK, 2006.

Paradoxical Pharmacology. 6th Melbourne International GPCR Forum, Melbourne, Australia, 2006.

Getting to the heart of asthma; can beta-blockers be used to treat asthma? Australia’s Medicines Research Conference, Melbourne, Australia, 2006.

Beta-blockers as possible asthma therapy. Kansas City, MO, USA, 2006.

Inverse Agonists as signaling enhancers. CHI-organized GPCR Symposium, La Jolla, CA, USA, 2006.

Getting to the heart of asthma; can beta-blockers be used to treat asthma? GlaxoSmithKline, RTP, NC, USA, 2006

Articles Written By Others About Our Research

Lipworth, B.J. and Williamson, P.A.: Think the impossible: beta-blockers for treating asthma. Clinical Science, 118: 115–120, 2010.

Ray, L.B.: Inverse Agonist to the Rescue. Sci. Signal. (formerly Science STKE) 2: ec76, 2009.

Penn, R.B.: Agonizing over agonism: Should asthmatics turn their ß-receptors on or off? Proc. Nat. Acad. Sci. 106: 2095-2096. 2009.

Lipworth, B.J. and Williamson, P.A.: ß-blockers for asthma: a double-edged sword? The Lancet 3: 104-105, 2009.

Chupp, G.L: Say what, beta-blockers for asthma? Am J Respir Cell Mol Biol. 38: 249-250, 2008.

Abbott, A.: Beta-blocker goes on trial as asthma therapy. Nature. 432: 7, 2004.

Ellis, C.: Timing is everything. Nature Reviews – Drug Discovery. 3: 387, 2004.

Martindale, D.: What doesn’t kill you. New Scientist. p.38-41Oct. 25, 2003.

Black J.W. and Shankley N.P.: Drug receptors. Inverse agonists exposed. Nature. 374: 214-5, 1995.


  • American Association for the Advancement of Science
  • American Society for Pharmacology and Experimental Therapeutics
  • British Pharmacological Society
  • New York Academy of Sciences
  • IUPHAR Adrenoceptor Classification Committee
  • American Association of Colleges of Pharmacy

Editorial Appointments

  • Senior Editor, British Journal of Pharmacology
    • Co-Editor for "A Special Issue Celebrating the Life and Work of James Whyte Black," Br. J. Pharmacol. Vol. 160, Supplement 1, 2010.
    • Co-Editor for Special Issue on Respiratory Pharmacology. Br. J. Pharmacol. 2011.
  • Naunyn-Schmiedeberg’s Archives of Pharmacology
  • Journal of Receptors and Signal Transduction